Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TTK | P33981 | 2/20 | 0.35 |
| ▸ | FEN1 | P39748 | 3/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.33 |
| ▸ | ULK1 | O75385 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25613086 | 0.97 | JAK3 (0.46) | JAK3LRRK2CDK1JAK2JAK1 | |
| SCHEMBL25613082 | 0.96 | JAK3 (0.48) | JAK3LRRK2CDK1JAK2JAK1 | |
| SCHEMBL25613062 | 0.94 | JAK3 (0.39) | JAK3CDK1JAK2JAK1TTK | |
| SCHEMBL25613085 | 0.90 | ROCK1 (0.41) | JAK3FEN1ROCK1 | |
| SCHEMBL25613083 | 0.87 | LRRK2 (0.40) | JAK3LRRK2JAK1 | |
| SCHEMBL25613079 | 0.86 | FEN1 (0.34) | JAK3FEN1ROCK1 | |
| SCHEMBL25613060 | 0.85 | TTK (0.38) | JAK3LRRK2TTKFEN1 | |
| SCHEMBL25613074 | 0.85 | PRKCZ (0.44) | ROCK1 | |
| SCHEMBL25613078 | 0.84 | PIK3CD (0.33) | JAK3FEN1 | |
| SCHEMBL25613081 | 0.84 | LRRK2 (0.41) | LRRK2TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | JAK3 3456/4885LRRK2 882/4885CDK1 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.